Tips & Tricks: GPC/SEC Peak Identification in GPC/SEC - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Tips & Tricks: GPC/SEC Peak Identification in GPC/SEC


The Column
Volume 6, Issue 22

Analysing a complex mixture of unknown macromolecules and low molar mass compounds is often challenging in GPC/SEC. A disadvantage of the most commonly used detector, the very universal but unspecific refractive index (RI) detector, is that this detector only provides concentration information and no information about the chemistry. In addition, various positive and negative peaks besides the pure sample peaks in a GPC/SEC run are normal. However, only when the chemical structures of the polymer components are known can sophisticated separation techniques, such as GPC/SEC, liquid adsorption chromatography (LAC) or liquid adsorption chromatography under critical conditions (LACCC) be properly adapted. Also, advanced detection such as on-line light scattering or triple detection requires the knowledge of the chemistry, since these techniques need specific sample related constants (e.g., the refractive index increment dn/dc). Therefore peak identification or substance identification can be very important in GPC/SEC, especially when establishing new methods. There are several possibilities for GPC/SEC users to identify peaks or to learn more about sample chemistry.

Click here for the full article in The Column

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
38%
Breakthrough designations
13%
Protecting the supply chain
38%
Expedited reviews of drug submissions
13%
More stakeholder involvement
0%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests
USP Faces New Challenges
Source: The Column,
Click here